John B Potts

US Patent:

7169567, Jan 30, 2007

Filed:

Dec 31, 1998

Appl. No.:

09/869565

Inventors:

Thomas J. Gardella - Needham MA, US
Henry M. Kronenberg - Belmont MA, US
John T. Potts - Newton MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

G01N 33/567
C12N 5/06
C12N 15/63
C07K 14/72
C07H 21/04

US Classification:

435 721, 435325, 435455, 530350, 536 235

Abstract:

The invention provides a novel PTH receptor polypeptide, rΔNt, characterized by a deletion of the extracellular amino-terminus, ligand binding domain of the receptor. Additionally disclosed are nucleic acid molecules encoding the receptor. The receptor has a minimal domain for ligand binding and is useful in screening assays designed for the identification of agonists and antagonists of PTH receptor activity.

US Patent:

7521528, Apr 21, 2009

Filed:

Jan 24, 2003

Appl. No.:

10/542704

Inventors:

Thomas J. Gardella - Needham MA, US
Henry M. Kronenberg - Boston MA, US
John T. Potts - Charlestown MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C07K 14/635

US Classification:

530324, 530325, 530326, 530399, 514 12

Abstract:

The present invention relates to methods of treatment of mammalian conditions characterized by decreases in bone mass with conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs containing PTH polypeptide derivatives containing at least one Glu or Lys substitution at position 6 and/or 10, some with installed lactam bridges between the side chains of Lys and Glu. The invention provides derivatives of PTH (1-34), PTH(1-33), PTH(1-32), PTH(1-31), PTH(1-30), PTH(1-29), PTH(1-28), PTH(1-27), PTH(1-26), PTH(1-25), PTH(1-24), PTH(1-23), PTH(1-22), PTH (1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), PTH(1-10) and PTH(1-9) polypeptide. The invention also provides methods of preparing the PTH analogs. Further, the invention encompasses treating conditions that are characterized by undesired bone loss or by the need for bone growth, e. g.

US Patent:

7985835, Jul 26, 2011

Filed:

Nov 13, 2006

Appl. No.:

11/598011

Inventors:

Thomas J. Gardella - Needham MA, US
Henry M. Kronenberg - Belmont MA, US
John T. Potts - Newton MA, US
Harald Jüppner - Cambridge MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 38/08
A61K 38/10
A61K 38/22
A61K 51/00
A61K 103/10
A61P 19/08

US Classification:

530327, 530328, 514 11, 514 53, 514 167, 514 215, 514 216, 424 111

Abstract:

Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.

US Patent:

20030153041, Aug 14, 2003

Filed:

Oct 9, 2002

Appl. No.:

10/267730

Inventors:

Gino Segre - Wayland MA, US
Henry Kronenberg - Belmont MA, US
John Potts - West Newton MA, US
Ernestina Schipani - Boston MA, US

Assignee:

The General Hospital Corporation, a Massachusetts corporation

International Classification:

C12P021/02
C12N005/06
C07K014/705
C07H021/04

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.

US Patent:

20030166838, Sep 4, 2003

Filed:

Jul 11, 2002

Appl. No.:

10/192673

Inventors:

Thomas Gardella - Needham MA, US
Henry Kronenberg - Belmont CA, US
John Potts - Newton MA, US

International Classification:

C07K007/08
C07K007/06

US Classification:

530/327000, 530/328000, 530/329000

Abstract:

Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing said peptides, and synthetic and recombinant methods for producing said peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.

US Patent:

20040176568, Sep 9, 2004

Filed:

May 30, 2002

Appl. No.:

10/157076

Inventors:

F. Bringhurst - Walpole MA, US
Hisashi Takasu - Mishima City, JP
Thomas Gardella - Needham MA, US
John Potts - West Newton MA, US

Assignee:

The General Hospital Corporation

International Classification:

A61K038/16
C07K014/00

US Classification:

530/324000, 514/012000

Abstract:

Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (a) XValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSer MetXArgValGluTrpLeuArgLysLysLeu (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof;  wherein: Xis Ser, Ala or Gly; and Xis Glu or Arg, provided that said peptide is not hPTH(1-26)NH, hPTH(1-27)NHor hPTH(1-28)NH.

US Patent:

20050203012, Sep 15, 2005

Filed:

Oct 7, 2004

Appl. No.:

10/959605

Inventors:

F. Richard Bringhurst - Walpole MA, US
Hisashi Takasu - Mishima City, JP
Thomas Gardella - Needham MA, US
John Potts - West Newton MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K038/17

US Classification:

514012000, 514013000

Abstract:

Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:

US Patent:

20050272660, Dec 8, 2005

Filed:

Jul 8, 2005

Appl. No.:

11/176735

Inventors:

Thomas Gardella - Needham MA, US
Henry Kronenberg - Belmont MA, US
John Potts - Newton MA, US

International Classification:

A61K038/22
C12P021/06
C12N001/21

US Classification:

514013000, 530326000, 435069100, 435320100, 435252300

Abstract:

Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.